MedPath

Opsys bulking agent bij mannelijke incontinentie

Suspended
Conditions
mannelijk incontinentiebulking stofmale incontinencebulking agent
Registration Number
NL-OMON26801
Lead Sponsor
ot sponsored trialperformer ZGT and Jeroen Bosch Ziekenhuis
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Suspended
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

•Subject remains dry at night.

•Ability to voluntarily stop micturition.

Exclusion Criteria

•Post-prostatectomy radiotherapy or brachytherapy.

•Subject radiated as treatment of Prostate Cancer, being this interstitial or external, neo-adjuvant, therapeutic or adjuvant.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The main study endpoint is whether treatment was successful, based on the two 24 h pad weight test (PWT) before and after treatment. The success rate of the procedure will be assessed according to the following criteria presented in Table 2.<br><br /><br /><br>Table 2. Criteria for defining treatment success, improvement and failure.<br /><br>ResultCriteria<br /><br>EndpointActual valueEndpointActual value<br>SUCCESS24-h PWT0 -3 gORVoiding diary <br>(Count pads)0 pads<br /><br>IMPROVEMENT24-h PWT¡Ý 50% reductionORVoiding diary <br /><br>(Count pads)¡Ý 50% less usage of pads<br /><br>FAILUREUnable to meet the previous criteria<br><br>
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath